Dow Down0.59% Nasdaq Down0.82%

Sunesis Pharmaceuticals, Inc. (SNSS)

-NasdaqCM
0.51 Down 0.01(1.92%) 1:20PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Sunesis Pharmaceuticals, Inc.
395 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States - Map
Phone: 650-266-3500
Fax: 650-266-3501
Website: http://www.sunesis.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:39

Business Summary 

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; developing SNS-062, a non-covalently binding inhibitor of the human protein Bruton’s tyrosine kinase; The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Sunesis Pharmaceuticals, Inc.

Corporate Governance 
Sunesis Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 8. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 6; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Daniel N. Swisher Jr., 53
Chief Exec. Officer, Pres and Director
708.00K0.00
Mr. Eric H. Bjerkholt , 56
Chief Financial Officer, Exec. VP of Corp. Devel. & Fin. and Corp. Sec.
522.00K0.00
Mr. Gene C. Jamieson ,
VP of Technical Operations
N/AN/A
Dr. Deborah A. Thomas Ph.D.,
Sr. VP of Regulatory Affairs, Quality Assurance and Non-Clinical Devel.
N/AN/A
Dr. Mary G. Bolton M.D., Ph.D.,
VP of Clinical Devel.
N/AN/A
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders